PT2640371T - Vasoprotective and cardioprotective antidiabetic therapy - Google Patents

Vasoprotective and cardioprotective antidiabetic therapy

Info

Publication number
PT2640371T
PT2640371T PT117876557T PT11787655T PT2640371T PT 2640371 T PT2640371 T PT 2640371T PT 117876557 T PT117876557 T PT 117876557T PT 11787655 T PT11787655 T PT 11787655T PT 2640371 T PT2640371 T PT 2640371T
Authority
PT
Portugal
Prior art keywords
vasoprotective
antidiabetic therapy
cardioprotective
cardioprotective antidiabetic
therapy
Prior art date
Application number
PT117876557T
Other languages
Portuguese (pt)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PT2640371T publication Critical patent/PT2640371T/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
PT117876557T 2010-11-15 2011-11-15 Vasoprotective and cardioprotective antidiabetic therapy PT2640371T (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP10191261 2010-11-15
US41554510P 2010-11-19 2010-11-19
US42140010P 2010-12-09 2010-12-09
EP11168317 2011-05-31
US201161492391P 2011-06-02 2011-06-02
EP11170992 2011-06-22

Publications (1)

Publication Number Publication Date
PT2640371T true PT2640371T (en) 2020-04-17

Family

ID=65948805

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117876557T PT2640371T (en) 2010-11-15 2011-11-15 Vasoprotective and cardioprotective antidiabetic therapy

Country Status (5)

Country Link
JP (2) JP7227107B2 (en)
KR (1) KR102117282B1 (en)
ES (1) ES2777890T3 (en)
MX (1) MX371198B (en)
PT (1) PT2640371T (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102289381B1 (en) * 2020-03-17 2021-08-17 주식회사 대웅테라퓨틱스 Pharmaceutical composition for prevention and treatment of hyperlipidemia and diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
EP2070539A1 (en) * 2002-08-21 2009-06-17 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine
DE10335027A1 (en) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt
AR074990A1 (en) * 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
EA029759B1 (en) * 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Antidiabetic medications comprising dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetic agents
UY32427A (en) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
JP2012525396A (en) * 2009-04-27 2012-10-22 レバレジオ コーポレイション Compositions and methods for treating insulin resistance and diabetes mellitus

Also Published As

Publication number Publication date
ES2777890T3 (en) 2020-08-06
JP7227107B2 (en) 2023-02-21
MX371198B (en) 2020-01-22
JP2020002159A (en) 2020-01-09
JP2021185204A (en) 2021-12-09
KR20190028571A (en) 2019-03-18
KR102117282B1 (en) 2020-06-01

Similar Documents

Publication Publication Date Title
IL225639A0 (en) Vasoprotective and cardioprotective antidiabetic therapy
HK1206004A1 (en) Ingenol-3-acylates iii and ingenol-3-carbamates -3- iii -3-
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
EP2606031A4 (en) Autotaxin inhibitors and uses thereof
PL2730564T3 (en) Heterocycle amines and uses thereof
SG10201506238SA (en) Heteroaryls And Uses Thereof
IL225607A0 (en) Heteroaryls and uses thereof
HK1167597A1 (en) Dodeca-2e,4e-diene amides and their use as medicaments and cosmetics -2e4e-
ZA201205425B (en) Treatment with vb-201
GB0921001D0 (en) Products and uses
HRP20182083T1 (en) Novel combination and use
IL223067A0 (en) Processes and intermediates
EP2608785A4 (en) Lipomacrocycles and uses thereof
GB201007202D0 (en) Product and uses
EP2529013A4 (en) Novel -glucosidase and uses thereof
GB201014020D0 (en) Thermal treatment
GB0912744D0 (en) Methods and uses
PT2640371T (en) Vasoprotective and cardioprotective antidiabetic therapy
HK1162526A1 (en) Glp-1 derivatives and uses thereof glp-1
PL2491021T3 (en) Novel acylpiperazinones and their use as pharmaceuticals
GB201117416D0 (en) Processes and intermediates
GB201001750D0 (en) Composite and process thereof
GB0903145D0 (en) Medicaments uses and methods
EP2638160A4 (en) Nuclions and ribocapsids
GB201017214D0 (en) Processes and intermediates